Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of January 2026
Chanel Holden @Chanel Holden
Platinum member since January 2017

Location: United States

Gender: Female

Asset investment style: Quantitative fundamental analysis

Market capitalization:

$8,135,691talents

Virtual portfolio value:

$5,225,820talents

Net overall return per annum:

20.01%

AYA current rank order:

#9

Asset investment philosophy:
Chanel Holden trades U.S. stocks with the top #1 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 40,963 +2,108.33% $310,909
UBXG U-BX Technology Ltd. Ordinary Shares $0.34 $3.98 36,511 +1,070.59% $132,900
UMAC Unusual Machines Inc. Common Stock $1.87 $18.73 6,638 +901.60% $111,917
SXTP 60 Degrees Pharmaceuticals Inc. Common Stock $0.15 $1.34 75,600 +793.33% $89,964
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 2,096 +589.24% $86,083
VATE INNOVATE Corp. Common Stock $0.53 $4.14 21,396 +681.13% $77,240
SSNT SilverSun Technologies Inc. Common Stock $18.59 $130.48 593 +601.88% $66,351
NTZ Natuzzi S.p.A. $2.21 $11.92 6,612 +439.37% $64,203
CDNS Cadence Design Systems Inc. Common Stock $29.82 $150.85 490 +405.87% $59,305
LGVN Longeveron Inc. Class A Common Stock $3.45 $26.25 2,122 +660.87% $48,382
Sum $1,047,254

Top 20 influencers

#1 - #5 #6 - #10 #11 - #15 #15 - #20
@alin
@Andy Yeh Alpha

Blog+More

Fed minutes reflect gradual interest rate normalization in response to high inflation risk.

Dan Rochefort

2018-02-15 07:43:00 Thursday ET

Fed minutes reflect gradual interest rate normalization in response to high inflation risk.

Fed minutes reflect gradual interest rate normalization in response to high inflation risk. FOMC members revise up the economic projections made at the Dece

+See More

U.S. regulatory agencies may consider broader economic issues in their antitrust probe into Amazon, Apple, Facebook, and Google.

Joseph Corr

2019-07-03 11:35:00 Wednesday ET

U.S. regulatory agencies may consider broader economic issues in their antitrust probe into Amazon, Apple, Facebook, and Google.

U.S. regulatory agencies may consider broader economic issues in their antitrust probe into tech titans such as Amazon, Apple, Facebook, and Google etc. Hou

+See More

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution.

Monica McNeil

2019-01-04 11:41:00 Friday ET

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution.

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution. Xi sends a congratulatory message to mark 40 years sin

+See More

AYA finbuzz podcast offers fresh insights into the latest stock market topics and economic trends for better stock investment decisions.

Daphne Basel

2019-09-30 07:33:00 Monday ET

AYA finbuzz podcast offers fresh insights into the latest stock market topics and economic trends for better stock investment decisions.

AYA Analytica finbuzz podcast channel on YouTube September 2019 In this podcast, we discuss several topical issues as of September 2019: (1) Former

+See More

President Trump may reluctantly sign the congressional border wall deal in order to avert another U.S. government shutdown.

Apple Boston

2019-02-13 11:00:00 Wednesday ET

President Trump may reluctantly sign the congressional border wall deal in order to avert another U.S. government shutdown.

President Trump may reluctantly sign the congressional border wall deal in order to avert another U.S. government shutdown. With his executive power to decl

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More